US Bancorp
AVBP icon

US Bancorp’s ArriVent BioPharma AVBP Stock Holding History

US Bancorp’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.5K Buy
1,510
+288
+24% +$8.5K ﹤0.01% 2771
2026
Q1 		$28.2K Buy
1,222
+111
+10% +$2.51K ﹤0.01% 2949
2025
Q4 		$22.4K Sell
1,111
-176
-14% -$3.66K ﹤0.01% 3033
2025
Q3 		$23.7K Buy
1,287
+160
+14% +$3.14K ﹤0.01% 3001
2025
Q2 		$24.5K Buy
1,127
+805
+250% +$16.7K ﹤0.01% 3094
2025
Q1 		$5.95K Buy
322
+217
+207% +$5.31K ﹤0.01% 3606
2024
Q4 		$2.8K Buy
+105
New +$3.01K ﹤0.01% 3792

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

US Bancorp's AVBP Position: Q2 2026 in Review

US Bancorp increased its ArriVent BioPharma (AVBP) stake by 24% in Q2 2026, buying an estimated $8.5K and bringing the position to 1,510 shares worth $52.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2771.

US Bancorp first reported a position in AVBP in Q4 2024 and has held it in 7 quarters since. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • US Bancorp held 1,510 shares of ArriVent BioPharma worth $52.5K as of Q2 2026.
  • US Bancorp bought 288 ArriVent BioPharma shares in Q2 2026, an estimated $8.5K.
  • ArriVent BioPharma made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2771 holding.
  • US Bancorp first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 7 quarters since.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.